Base de dados : MEDLINE
Pesquisa : D03.383.663.283.446.520.451 [Categoria DeCS]
Referências encontradas : 147 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 147 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:11482149
[Au] Autor:Pitrák V; Hadacová I; Hochová I; Hoch J
[Ad] Endereço:Chirurgická klinika 2. LF UK a FNM, Praha.
[Ti] Título:[Serious surgical complications associated with chronic anticoagulant therapy].
[Ti] Título:Závazné chirurgické komplikace chronické antikoagulacní lécby..
[So] Source:Rozhl Chir;80(6):290-3, 2001 Jun.
[Is] ISSN:0035-9351
[Cp] País de publicação:Czech Republic
[La] Idioma:cze
[Ab] Resumo:Chronic anticoagulant treatment is administered mostly for cardiological reasons. Cumarin derivatires are used in the majority of cases (Warfarin, Pelentan). It is necessary to monitor this treatment regularly and to control the dose according to the INR value. Different complications can occur; the haemorrhage represents a serious one. The authors discuss several aspects of anticoagulant therapy and possible prevention of the complications. The importance of the problems is demonstrated on the authors' clinical experience--two cases of haemorrhage after Warfarin administration simulating an acute surgical event.
[Mh] Termos MeSH primário: Anticoagulantes/efeitos adversos
Hemorragia/induzido quimicamente
[Mh] Termos MeSH secundário: Abdome Agudo/diagnóstico
Abdome Agudo/etiologia
Músculos Abdominais
Idoso
Idoso de 80 Anos ou mais
Biscumacetato de Etila/efeitos adversos
Feminino
Hematoma/induzido quimicamente
Hemorragia/diagnóstico
Hemorragia/prevenção & controle
Seres Humanos
Masculino
Espaço Retroperitoneal
Varfarina/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anticoagulants); 08KL644731 (Ethyl Biscoumacetate); 5Q7ZVV76EI (Warfarin)
[Em] Mês de entrada:0108
[Cu] Atualização por classe:161206
[Lr] Data última revisão:
161206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:010803
[St] Status:MEDLINE


  2 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9640069
[Au] Autor:Prazanowski M; Pilacik B; Lutz W
[Ad] Endereço:Zakladu Diagnostyki Laboratoryjnej Instytutu Medycyny Pracy, Lodzi.
[Ti] Título:[Use of hypoprothrombinemia provocation test for early diagnosis of liver disease caused by harmful environmental agents].
[Ti] Título:Zastosowanie próby hipoprotrombinemii prowokowanej we wczesnej diagnostyce chorób watroby wywolanych przez czynniki srodowiskowe..
[So] Source:Pol Merkur Lekarski;4(21):154-7, 1998 Mar.
[Is] ISSN:1426-9686
[Cp] País de publicação:Poland
[La] Idioma:pol
[Ab] Resumo:The aim of this work has been to assess the feasibility of using Prothrombin Time (PT) Assay before and after administration of Pelentan (Hypoprothrombinemia Provocation (HPP) Test) for early detection of subclinical toxic hepatic injuries. The proposed modification of PT Assay is based on the observation that people with slight hepatic injury receiving small doses of Pelentan (diethylcoumarol) display remarkably longer PT than healthy people receiving similar doses of the chemical. The test group comprised 37 people occupationally exposed to hepatotoxic agents, 85 males permanently abusing alcohol, while 24 clinically healthy people, not exposed occupationally to the toxic agents served as the control. In addition, 26 hepatitis B and/or C virus carriers were also examined. The results show that: 1. HPP test enables assessment of hepatic function in patients with suspected hepatic injury and in people permanently abusing alcohol; 2. low value of serum prothrombin index 24 h and 48 h after the administration of Pelentan is indicative of the positive result of the test; 3. HPP test provides more information on the functional condition of liver than single PT determination by the Quick assay.
[Mh] Termos MeSH primário: Poluentes Ocupacionais do Ar/efeitos adversos
Anticoagulantes/efeitos adversos
Biscumacetato de Etila/efeitos adversos
Hipoprotrombinemias/diagnóstico
Hepatopatias/diagnóstico
Tempo de Protrombina
[Mh] Termos MeSH secundário: Adulto
Idoso
Alcoolismo/complicações
Doença Hepática Induzida por Substâncias e Drogas
Monitoramento Ambiental/métodos
Feminino
Seres Humanos
Hipoprotrombinemias/etiologia
Hepatopatias/complicações
Testes de Função Hepática
Masculino
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Air Pollutants, Occupational); 0 (Anticoagulants); 08KL644731 (Ethyl Biscoumacetate)
[Em] Mês de entrada:9807
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980626
[St] Status:MEDLINE


  3 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:7874379
[Au] Autor:Perlík F; Patzelová V
[Ad] Endereço:1st Department of Medicine, Faculty of Medicine, Charles University, Prague, Czech Republic.
[Ti] Título:Pharmacokinetics of ethyl biscoumacetate and its metabolite 7-hydroxy ethyl biscoumacetate in healthy volunteers.
[So] Source:Int J Clin Pharmacol Ther;32(11):622-4, 1994 Nov.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Disposition kinetics of ethyl biscoumacetate and its metabolite 7-hydroxy ethyl biscoumacetate were evaluated in ten healthy volunteers, after a single 300 mg oral dose of ethyl biscoumacetate. Serum concentrations of parent compound and its metabolite were measured by HPLC. The maximum serum ethyl biscoumacetate concentrations were reached 1.0-4.0 hours after drug dosing. From 3 hours after drug administration the concentration of the metabolite was always higher than the concentration of the parent compound. Geometric mean of elimination half-life was 0.66 hours for ethyl biscoumacetate and 2.03 hours for the 7-hydroxy ethyl metabolite.
[Mh] Termos MeSH primário: Biscumacetato de Etila/análogos & derivados
Biscumacetato de Etila/farmacocinética
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Cromatografia Líquida de Alta Pressão
Biscumacetato de Etila/sangue
Seres Humanos
Meia-Idade
Valores de Referência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
08KL644731 (Ethyl Biscoumacetate); 112222-66-9 (7-hydroxyethyl biscoumacetate)
[Em] Mês de entrada:9504
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:941101
[St] Status:MEDLINE


  4 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8478129
[Au] Autor:Pávek V; Bigl P
[Ad] Endereço:Department of Oral Surgery, 1st, Medical Faculty of Charles University, Prague, Czech Republic.
[Ti] Título:Stomatological treatment of patients with artificial heart valves: coagulation control and antibiotic cover.
[So] Source:Int Dent J;43(1):59-61, 1993 Feb.
[Is] ISSN:0020-6539
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Anticoagulantes/uso terapêutico
Assistência Odontológica para Pessoas com Deficiências
Próteses Valvulares Cardíacas
[Mh] Termos MeSH secundário: Adulto
Antibacterianos/administração & dosagem
Biscumacetato de Etila/administração & dosagem
Biscumacetato de Etila/uso terapêutico
Feminino
Heparina/administração & dosagem
Heparina/uso terapêutico
Seres Humanos
Masculino
Meia-Idade
Boca/cirurgia
Pré-Medicação
Extração Dentária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anticoagulants); 08KL644731 (Ethyl Biscoumacetate); 9005-49-6 (Heparin)
[Em] Mês de entrada:9305
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:930201
[St] Status:MEDLINE


  5 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8351679
[Au] Autor:Copie X; Pinquier JL; Letrait M; Paltiat MH; Pello JY; Rey E; Chanteclair G; de Lauture D; Olive G; Strauch G
[Ad] Endereço:Institut de Recherche Thérapeutique (IRT-Eclimed), Hôpital Cochin, Paris.
[Ti] Título:[Effect of dimethicone on pharmacokinetics and pharmacodynamics of ethyl biscoumacetate].
[Ti] Título:Effet du diméticone sur la pharmacocinétique et la pharmacodynamie du biscoumacétate d'éthyle..
[So] Source:Therapie;48(2):119-23, 1993 Mar-Apr.
[Is] ISSN:0040-5957
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:The influence of dimeticone (Gel de Polysilane Midy) on the pharmacokinetics and pharmacodynamics of oral ethyl biscoumacetate was studied in 6 healthy volunteers in a randomised single dose, two-way cross-over study. Each volunteer received at one week interval a single dose (300 mg) of ethyl biscoumacetate, either alone or with dimeticone. Ethyl biscoumacetate levels were measured in plasma for 24 hours. Pharmacodynamic parameters were measured for 96 hours. Ethyl biscoumacetate peak concentration was significantly higher when administered with dimeticone (40.3 +/- 25.3 mg/l vs 31.0 +/- 25.7 mg/l; p = 0.031), without significant change in the area under curve. Other pharmacokinetic and pharmacodynamic parameters did not differ significantly. The slight increase of the ethyl biscoumacetate bioavailability with dimeticone in repeated dosing might have pharmacodynamic consequence; a clinical trial should address this question.
[Mh] Termos MeSH primário: Biscumacetato de Etila/farmacologia
Biscumacetato de Etila/farmacocinética
Simeticone/farmacologia
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
[Pt] Tipo de publicação:CLINICAL TRIAL; ENGLISH ABSTRACT; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
08KL644731 (Ethyl Biscoumacetate); 8050-81-5 (Simethicone)
[Em] Mês de entrada:9309
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:930301
[St] Status:MEDLINE


  6 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:8266311
[Au] Autor:Olthof E; de Vries TW
[Ad] Endereço:Afd. Kindergeneeskunde, Academisch Ziekenhuis Groningen.
[Ti] Título:[Breast feeding and oral anticoagulants].
[Ti] Título:Borstvoeding en orale anticoagulantia..
[So] Source:Tijdschr Kindergeneeskd;61(5):175-7, 1993 Oct.
[Is] ISSN:0376-7442
[Cp] País de publicação:Netherlands
[La] Idioma:dut
[Ab] Resumo:Oral anticoagulants are frequently prescribed during lactation. Because these drugs could affect the hemostasis of the newborn, we did a literature search to find out whether precautions should be taken. It appeared that acenocoumarol and warfarin are not detectable in human milk. Besides the usual daily supplementation of 25 micrograms vitamin K for every breast-fed infant, precautions are not necessary. Phenprocoumon, ethylbiscoumacetate and phenindione are excreted in human milk and could affect neonatal hemostasis.
[Mh] Termos MeSH primário: Anticoagulantes/análise
Aleitamento Materno
Hemorragia/induzido quimicamente
Leite Humano/química
[Mh] Termos MeSH secundário: Acenocumarol/análise
Anticoagulantes/efeitos adversos
Biscumacetato de Etila/análise
Feminino
Seres Humanos
Lactente
Recém-Nascido
Femprocumona/análise
Varfarina/análise
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anticoagulants); 08KL644731 (Ethyl Biscoumacetate); 5Q7ZVV76EI (Warfarin); I6WP63U32H (Acenocoumarol); Q08SIO485D (Phenprocoumon)
[Em] Mês de entrada:9401
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:931001
[St] Status:MEDLINE


  7 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1629290
[Au] Autor:Pospísil J; Patzelová V; Perlík F
[Ad] Endereço:Department of Clinical Pharmacology, Charles University, Prague, Czechoslovakia.
[Ti] Título:Determination of ethyl biscoumacetate and its metabolite 7-hydroxyethyl biscoumacetate in human serum by high-performance liquid chromatography and mass spectrometry.
[So] Source:J Chromatogr;574(1):71-5, 1992 Feb 07.
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:An efficient reversed-phase high-performance liquid chromatographic method has been developed for the determination of ethyl biscoumacetate (EBA) and its metabolite in human serum, using the mu Bondapak C18 column and methanol-water-phosphoric acid (56:46.8:0.2, v/v/v) as the mobile phase. This method permitted the determination of both EBA and a metabolite in human serum. The latter has been mentioned by other authors only in urine samples, where significant concentrations were found. Identification of the metabolite as 7-hydroxyethyl biscoumacetate was based on its chromatographic separation, followed by isolation from the eluate and direct mass spectrometric identification. It has been found that the higher EBA concentrations in human serum described by Brodie et al. [J. Pharmacol. Exp. Ther., 106 (1952) 453] were caused by the insufficient resolving power of the spectrophotometric method used, leading to overlapping of the UV spectra of the parent drug and its metabolite.
[Mh] Termos MeSH primário: Biscumacetato de Etila/análogos & derivados
Biscumacetato de Etila/sangue
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Feminino
Seres Humanos
Masculino
Espectrometria de Massas
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
08KL644731 (Ethyl Biscoumacetate); 112222-66-9 (7-hydroxyethyl biscoumacetate)
[Em] Mês de entrada:9208
[Cu] Atualização por classe:131213
[Lr] Data última revisão:
131213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920207
[St] Status:MEDLINE


  8 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1519350
[Au] Autor:Sokol'nikov AA; Avramova LV; Kodentsova VM; Vrzhesinskaia OA; Goncharova NIu; Spirichev VB
[Ti] Título:[Kinetic characteristics of creatine kinase and hexokinase from rat skeletal muscles during dietary deficit of vitamin K and administration of pelentane].
[Ti] Título:Kineticheskie kharakteristiki kreatinkinazy i geksokinazy skeletnykh myshts krysy pri pishchevom defitsite vitamina K i vvedenii pelentana..
[So] Source:Ukr Biokhim Zh (1978);64(1):72-7, 1992 Jan-Feb.
[Is] ISSN:0201-8470
[Cp] País de publicação:Ukraine
[La] Idioma:rus
[Ab] Resumo:Kinetic parameters of rat creatine kinase isozymes at different vitamin K supply and treatment with antivitamin K--pelentan have been determined. MM-isozyme (skeletal muscle) has selective sensitivity to the vitamin K deficit, while BB and MB-isozymes (brain, kidney and heart) have not. The value KM for ATP of MM-isozymes increases, while maximal activity decreases. Pelentan treatment does not lead to the change of MM-creatine kinase affinity to ATP. Soluble hexokinase of skeletal muscle in rats with vitamin K deficiency and treated with pelentan has higher affinity to glucose as compared to normal rat enzyme. It has been supposed that skeletal muscle hexokinase exists in a particular molecular form under vitamin K deficiency.
[Mh] Termos MeSH primário: Creatina Quinase/metabolismo
Biscumacetato de Etila/administração & dosagem
Hexoquinase/metabolismo
Músculos/enzimologia
Deficiência de Vitamina K/metabolismo
[Mh] Termos MeSH secundário: Animais
Dieta
Isoenzimas
Cinética
Ratos
Ratos Endogâmicos
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Isoenzymes); 08KL644731 (Ethyl Biscoumacetate); EC 2.7.1.1 (Hexokinase); EC 2.7.3.2 (Creatine Kinase)
[Em] Mês de entrada:9210
[Cu] Atualização por classe:150505
[Lr] Data última revisão:
150505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920101
[St] Status:MEDLINE


  9 / 147 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:1492386
[Au] Autor:Sokol'nikov AA; Shinkevich TE; Kodentsova VN; Vrzhesinskaia OA; Spirichev VB
[Ti] Título:[Activity of menadione reductase and level of cytochrome B5 and P-450 in liver with varying supplies of vitamin K and administration of pelentan to rats].
[Ti] Título:Aktivnost' menadionreduktazy i soderzhanie tsitokhormov B5 i P-450 v pecheni pri razlichnoi obespechennosti krys vitaminom K i vvedenii pelentana..
[So] Source:Vopr Med Khim;38(5):15-7, 1992 Sep-Oct.
[Is] ISSN:0042-8809
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Content of cytochromes b5 and P-450 as well as activity of soluble menadione reductase were estimated in liver microsomes of rats deprived of vitamin K or maintained both on a diet containing excess of vicasol or antivitamin K-pelentan. Deficiency of vitamin K led to an increase in the specific activity of menadione reductase and in content of the cytochrome P-450. Administration of antivitamin K did not alter these parameters but caused an increase in the content of cytochrome b5, which was not changed in vitamin K deficiency. Dissimilar effects of alimentary deficiency in vitamin K and of pelentan administration suggest that administration of antivitamins K (although it allowed to discover alterations developed via the system of vitamin K-dependent carboxylation) could not be completely identified with alimentary vitamin K deficiency.
[Mh] Termos MeSH primário: Sistema Enzimático do Citocromo P-450/metabolismo
Citocromos b5/metabolismo
Biscumacetato de Etila/administração & dosagem
Microssomos Hepáticos/enzimologia
NAD(P)H Desidrogenase (Quinona)/metabolismo
Deficiência de Vitamina K/enzimologia
[Mh] Termos MeSH secundário: Animais
Masculino
Ratos
Ratos Wistar
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
08KL644731 (Ethyl Biscoumacetate); 9035-39-6 (Cytochromes b5); 9035-51-2 (Cytochrome P-450 Enzyme System); EC 1.6.5.2 (NAD(P)H Dehydrogenase (Quinone))
[Em] Mês de entrada:9303
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:920901
[St] Status:MEDLINE


  10 / 147 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:1473874
[Au] Autor:Sabo A; Stanulovic M; Jakovljevic V
[Ad] Endereço:Department of Pharmacology, Toxicology, and Clinical Pharmacology, School of Medicine, University of Novi Sad, Serbia.
[Ti] Título:Phytomenadione improves red cell deformability in laboratory animals.
[So] Source:Int J Clin Pharmacol Ther Toxicol;30(12):587-90, 1992 Dec.
[Is] ISSN:0174-4879
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The deformability of red blood cells (RBC) is one of the factors that determine whole blood rheology. Derivatives of vitamin K (phytomenadione, menadione, menadione bisulfite) are electron-transporting substances. The aim of this study was to investigate the possible influence of derivatives of vitamin K on erythrocyte deformability in studies in vivo--on rats and rabbits. The influence of vitamin K antagonist on erythrocyte deformability (ethylbiscumacetate) was also determined. Pentoxifylline known to affect RBC deformability was also included in the study as the control treatment. The study was performed on white laboratory rats and domestic rabbits. The blood was obtained from animals after single and multiple dosing of drugs. Blood sample was prepared and RBC filterability was assayed with a gravity driven filtration technique. Pentoxyfylline did not change erythrocyte deformability after single dose, but significantly improved erythrocyte deformability of laboratory animals after multiple application. Filterability values of the RBCs of the rats and rabbits increased significantly after single and multiple treatment with phytomenadione, while the two other derivatives, menadione and menadione bisulfite, did not change RBC deformability. Ethylbiscumacetate did not change erythrocyte deformability in rats after single dose.
[Mh] Termos MeSH primário: Deformação Eritrocítica/efeitos dos fármacos
Vitamina K 1/farmacologia
[Mh] Termos MeSH secundário: Animais
Biscumacetato de Etila/farmacologia
Feminino
Masculino
Pentoxifilina/farmacologia
Coelhos
Ratos
Vitamina K/análogos & derivados
Vitamina K/farmacologia
Vitamina K 3
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
08KL644731 (Ethyl Biscoumacetate); 12001-79-5 (Vitamin K); 723JX6CXY5 (Vitamin K 3); 84-80-0 (Vitamin K 1); SD6QCT3TSU (Pentoxifylline)
[Em] Mês de entrada:9302
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:921201
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde